- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05338775
Un estudio de talquetamab y teclistamab, cada uno en combinación con un inhibidor del receptor de muerte celular programada 1 (PD-1) para el tratamiento de participantes con mieloma múltiple en recaída o refractario (TRIMM-3)
Un estudio de fase 1b de anticuerpos biespecíficos de redirección de células T en combinación con inhibición de puntos de control para el tratamiento de participantes con mieloma múltiple en recaída o refractario
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Acceso ampliado
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Dresden, Alemania, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Hamburg, Alemania, 20246
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Alemania, 69120
- Universitaetsklinikum Heidelberg
-
Würzburg, Alemania, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Badalona, España, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Madrid, España, 28040
- Hosp Univ Fund Jimenez Diaz
-
Pamplona, España, 31008
- Clinica Univ. de Navarra
-
Salamanca, España, 37007
- Hosp Clinico Univ de Salamanca
-
-
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Colorado Blood Cancer Institute
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Estados Unidos, 10011
- The Blavatnik Family Chelsea Medical Center at Mount Sinai
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Wake Forest Baptist Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt Ingram Cancer Center
-
-
-
-
-
Montpellier, Francia, 34295
- CHU de Montpellier Hopital Saint Eloi
-
Nantes, Francia, 44093
- CHU de Nantes hotel Dieu
-
Poitiers, Francia, 86021
- CHU Poitiers - Hopital la Miletrie
-
Toulouse, Francia, 31059
- Institut Universitaire du Cancer Toulouse Oncopole
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Have documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
- Participants with relapsed or refractory disease that are not a candidate for available therapy with established clinical benefit
- Have measurable disease at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL); b) Urine M-protein level >= 200 milligrams (mg) per 24 hours; c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 milligrams/deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
- Prior antitumor therapy within 21 days prior to the first dose of study treatment (proteasome inhibitor [PI] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene -modified adoptive cell therapy or autologous stem cell transplant within 3 months)
- Prior therapy with PD-1 inhibitors, allogeneic stem cell transplant or solid organ transplant
- Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis
- Active Central Nervous System (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Live, attenuated vaccine within 4 weeks before the first dose of study treatment
- Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia [any grade] or peripheral neuropathy to Grade <= 2)
- Received a cumulative dose of corticosteroids equivalent to >= 140 milligrams (mg) of prednisone within the 14-day period before the start of study treatment administration
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1: Dose Escalation
Participants will receive either talquetamab (treatment regimen A) or teclistamab (treatment regimen B) with a PD-1 inhibitor biweekly. |
Talquetamab will be administered as a subcutaneous (SC) injection. Teclistamab will be administered as a SC injection. The PD-1 inhibitor will be administered as an intravenous injection. |
|
Experimental: Part 2: Dose Expansion
Participants will receive either treatment regimen A or treatment regimen B with a PD-1 inhibitor at the dose levels identified in Part 1. |
Talquetamab will be administered as a subcutaneous (SC) injection. Teclistamab will be administered as a SC injection. The PD-1 inhibitor will be administered as an intravenous injection. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
Periodo de tiempo: Up to 2 years 5 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years 5 months
|
|
Number of Participants with Adverse Events (AEs) by Severity
Periodo de tiempo: Up to 2 years 5 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event. |
Up to 2 years 5 months
|
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
Periodo de tiempo: Up to 2 years 5 months
|
Number of participants with abnormalities in clinical laboratory assessments (serum chemistry and hematology) will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Dose-Limiting Toxicity (DLTs)
Periodo de tiempo: Up to 2 years 5 months
|
The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 2 years 5 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Response Rate (ORR)
Periodo de tiempo: Up to 2 years 5 months
|
ORR is defined as the percentage of participants who achieve partial response (PR) or better according to the International Myeloma Working Group (IMWG) 2016 criteria. |
Up to 2 years 5 months
|
|
Very Good Partial Response (VGPR) or Better Response Rate
Periodo de tiempo: Up to 2 years 5 months
|
VGPR or better response rate is defined as the percentage of participants who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Complete Response (CR) or Better Response Rate
Periodo de tiempo: Up to 2 years 5 months
|
CR or better response rate is defined as the percentage of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Stringent Complete Response (sCR) Rate
Periodo de tiempo: Up to 2 years 5 months
|
sCR rate is defined as the percentage of participants who achieve an sCR according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Duration of Response
Periodo de tiempo: Up to 2 years 5 months
|
Duration of response is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG 2016 criteria or death due to any cause, whichever occurs first. |
Up to 2 years 5 months
|
|
Time to Response
Periodo de tiempo: Up to 2 years 5 months
|
Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better. |
Up to 2 years 5 months
|
|
Serum Concentrations of Talquetamab
Periodo de tiempo: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of Talquetamab using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Serum Concentrations of Teclistamab
Periodo de tiempo: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of Teclistamab using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Serum Concentrations of PD-1 Inhibitor
Periodo de tiempo: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of PD-1 inhibitor using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-Talquetamab Antibodies
Periodo de tiempo: Up to 2 years 5 months
|
Number of participants with anti-talquetamab antibodies will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-Teclistamab Antibodies
Periodo de tiempo: Up to 2 years 5 months
|
Number of participants with anti-teclistamab antibodies will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-PD-1 Inhibitor Antibodies
Periodo de tiempo: Up to 2 years 5 months
|
Number of participants with anti-PD-1 inhibitor antibodies will be reported. |
Up to 2 years 5 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research and Development, LLC Clinical Trial, Janssen Research & Development, LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CR109168
- 2021-005073-22 (Número EudraCT)
- 64407564MMY1005 (Otro identificador: Janssen Research & Development, LLC)
- 2022-502681-24-00 (Identificador de registro: EUCT number)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .